Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Sulforaphane, a bioactive compound found in cruciferous vegetables like broccoli, has attracted attention for its potential anti-inflammatory and antioxidant properties. In the context of Inflammatory Bowel Disorders (IBD), including Crohn’s disease and ulcerative colitis, several preclinical studies have explored sulforaphane's effects. Animal models of colitis have shown that sulforaphane administration may reduce mucosal inflammation, oxidative stress, and certain pro-inflammatory cytokines, possibly through activation of the Nrf2 pathway and inhibition of NF-κB signaling. These mechanisms suggest a theoretical benefit for mitigating intestinal inflammation characteristic of IBD. However, clinical evidence in humans is very limited. Only a handful of small pilot studies or indirect evidence (e.g., biomarker changes in healthy subjects or those with other inflammatory conditions) exist, and no large, controlled clinical trials have directly examined sulforaphane supplementation in patients with IBD. As such, while there is scientific rationale and promising preclinical data, the evidence supporting sulforaphane for IBD remains preliminary, warranting a low-to-moderate rating. Further robust human studies are needed to determine efficacy, optimal dosing, and safety in this population.

More about Sulphoraphane
More about Inflammatory Bowel Disorders

Other ingredients used for Inflammatory Bowel Disorders

Other health conditions supported by Sulphoraphane

Products containing Sulphoraphane